Brief: Calithera Biosciences And Antengene Enter Worldwide License Agreement For Development & Commercialization Of Cb-708
17/05/2021 13:55
May 17 (Reuters) - Antengene Corporation Ltd 6996.HK :
* CALITHERA BIOSCIENCES AND ANTENGENE ENTER WORLDWIDE
LICENSE AGREEMENT FOR DEVELOPMENT & COMMERCIALIZATION OF CB-708
* CALITHERA BIOSCIENCES INC - UNDER AGREEMENT, WILL RECEIVE
UPFRONT PAYMENT AND POTENTIAL DEVELOPMENT, REGULATORY, SALES
MILESTONES OF UP TO $255.0 MILLION
* CALITHERA BIOSCIENCES INC - UNDER AGREEMENT, ANTENGENE
INVESTMENT LTD WILL RECEIVE EXCLUSIVE, WORLDWIDE RIGHTS TO
DEVELOP AND COMMERCIALIZE CB-708
Source text for Eikon: ID:nGNX4LVgFk
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106